Front Cover: Chromenone Derivatives as CRM1 Inhibitors for Targeting Glioblastoma (ChemBioChem 15/2025)

The cover image illustrates the inhibition of the nuclear export receptor CRM1 by a small molecule inhibitor (in red) that covalently binds to cysteine at position 528. CRM1, a ring-shaped protein, is overexpressed in several human cancers, including glioblastoma (GBM). Its inhibition can disrupt three key oncogenic signaling pathways that drive GBM progression. CRM1 facilitates the nuclear export of proteins containing a nuclear export signal through the nuclear pore complex (depicted in yellow), which is embedded in the nuclear envelope, from the nucleus to the cytoplasm. More details can be found in the article 10.1002/cbic.202500195 by Wolfgang Link and co-workers.